Friday, June 14, 2019
10:31 AM EST – Prometic Life Sciences Inc. : Announced that four abstracts highlighting Prometic’s progress in developing PBI-4050 as a potential treatment for both acute kidney injury and chronic kidney disease is being presented at the 56th Congress of the European Renal Association – European Dialysis and Transplant Association, ending Sunday in Budapest. (T.PLI) shares were up $0.005 at 0.03.
Stocks in Play: Prometic Life Sciences Inc., Fri, 14 Jun 2019 10:36:01 EST